DB15850InvestigationalVaccines
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma .... Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells.
- Code names
- IMM-101
Resolves to
Compound
What you can answer from here — as of July 18, 2023
Which companies are running trials of IMM-101, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account